Investor Presentaiton

Oncology Hematology Cell Therapy Immunology Cardiovascular milvexian (FXla inhibitor) Indication Phase/Study # of Patients Design Endpoints Status CT Identifier Secondary Stroke Prevention Phase III - LIBREXIA-STROKE Non-BMS Sponsored* N = 15,000 • Milvexian 25 mg BID + background antiplatelet therapy • Placebo + background antiplatelet therapy • Primary: Time to first occurrence of ischemic stroke Key secondary: • Time to first occurrence of any component of the composite of CVD, MI, or ischemic stroke • Time to first occurrence of ischemic stroke Recruiting • Projected data readout 2026 (event driven) NCT05702034 ll Bristol Myers Squibb Q3 2023 Results Acute Coronary Syndrome Phase III LIBREXIA-ACS - Non-BMS Sponsored* N = 16,000 • Milvexian 25 mg BID + background antiplatelet therapy • Placebo + background antiplatelet therapy Note: participants enrolled within 7 days of ACS +/- catheterization Primary: Time to first occurrence of MACE Key secondary: Non-Valvular Atrial Fibrillation 1 Phase III LIBREXIA-AF Non-BMS Sponsored* N = 15,500 • Milvexian 100 mg BID Eliquis • Primary: Time to first occurrence of composite endpoint of stroke & non-CNS system embolism Time to first occurrence of any component Key secondary: of the composite of MAVE • ⚫ Recruiting Projected data readout 2026 (event driven) *Trials conducted by Janssen NCT05754957 Time to first occurrence of ISTH major bleeding Time to first occurrence of the composite of ISTH major & CRNM bleeding ⚫ Recruiting Projected data readout 2027 (event driven) NCT05757869 Not for Product Promotional Use 54

View entire presentation